ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Running, not enrolling · Phase 2

Conditions studied: HER2 Positive Metastatic Breast Cancer

In brief

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd

Key facts

Study ID: NCT04829604
Run by: Ambrx, Inc.
People needed: 72
Starts: 2021-10-26
Expected to finish: 2027-06-01
Last updated by the study team: 2026-03-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Research Site — Los Angeles, California, United States
Research Site — Newport Beach, California, United States
Research Site — San Francisco, California, United States
Research Site — Whittier, California, United States
Research Site — Atlanta, Georgia, United States
Research Site — Chicago, Illinois, United States
Research Site — Louisville, Kentucky, United States
Research Site — Silver Spring, Maryland, United States
Research Site — Boston, Massachusetts, United States
Research Site — St Louis, Missouri, United States
Research Site — Omaha, Nebraska, United States
Research Site — Las Vegas, Nevada, United States
Research Site — Camden, New Jersey, United States
Research Site — New Hyde Park, New York, United States
Research Site — New York, New York, United States
Research Site — Shirley, New York, United States
Research Site — The Bronx, New York, United States
Research Site — Portland, Oregon, United States
Research Site — Tigard, Oregon, United States
Research Site — Philadelphia, Pennsylvania, United States
Research Site — Dallas, Texas, United States
Research Site — Houston, Texas, United States
Research Site — San Antonio, Texas, United States
Research Site — Norfolk, Virginia, United States
Research Site — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.